Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Medical
- Device
- Packaging & Containers
- Diagnostic
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28752
As a result of Baxter International Inc.'s sale of its transfusion therapies division to the Licensor, the Licensee has certain Agreements with the Licensor.
IPSCIO Record ID: 3625
(a)
an exclusive (even as to Baxter) royalty-bearing right and license under the Licensed Patents and Licensed Know-How to make, have made, assemble, use, sell, offer for sale, distribute, import and export
(i)
Platelet Products solely for sale in the Platelet Territory;
(ii)
Plasma Products solely for sale in the Plasma Territory;
(iii)
RBC Products solely for sale in the RBC Territory; and
(iv)
Residual Products solely for sale in the Residual Territory; and
(b) a nonexclusive, royalty-bearing right and license to use, reproduce, display, translate, distribute copies of, and to modify and create derivative works of the Licensed Materials within the respective parts of the Territory set forth.
The Intercept Blood System, which is based on our proprietary Helinx technology for controlling biological replication, is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells.
The rights granted apply for blood safety, cancer and infectious disease.
IPSCIO Record ID: 4410
(a) an exclusive (even as to Baxter) royalty-bearing right and license under the Licensed Patents and Licensed Know-How to make, have made, assemble, use, sell, offer for sale, distribute, import and export
(i) Platelet Products solely for sale in the Platelet Territory;
(ii) Plasma Products solely for sale in the Plasma Territory;
(iii) RBC Products solely for sale in the RBC Territory; and
(iv) Residual Products solely for sale in the Residual Territory.
Parties have developed technology for the inactivation of pathogens in blood and blood components (the “INTERCEPT Blood Systemâ€).
“INTERCEPT Illuminator†means a proprietary illumination device, including operating software and data management system including source code for each, developed for use with Platelet Sets and Plasma Sets.
“ESOL Solution†means a proprietary red blood cell storage solution, also known as erythrosol in all formulations thereof.
“Conversion Kit†means a disposable set having Intersol Solution which permits the preparation of single donor platelets collected on a non-Baxter apheresis collection platform to interface with the Platelet System.
“Plasma Sets†means disposable processing sets, including without limitation, single unit and jumbo configurations, for inactivation of pathogens in plasma components of blood, containing the raw material amotosalen (“S-59â€) or other psoralen compounds.
“Platelet Product†means Platelet Systems, Conversion Kits and Storage Solution Containers.
“Platelet Sets†means disposable processing sets for the inactivation of pathogens in platelet components of blood, containing the raw material amotosalen (“S-59â€) or other psoralen compounds
IPSCIO Record ID: 233460
Licensed Invention means any composition of matter, method or process relating to alterations in the lipid structure of biological material; e.g., including, but not limited to, delipidization of soft tissue, e.g., atheroma, inactivation of lipid-enveloped organisms, e.g., viruses, as well as know-how, materials, trademarks, copyrights and technology which has or may be acquired by or on behalf of either or both of the Licensor, and which is useful in or necessary toward the development, optimization and/or commercialization of any composition of matter, method or process defined by the claims of the Licensed Patents.
Technology is based on a process of selective, systemic removal of lipids from plasma, or blood without red cells. This process is known as plasma delipidation. The process is designed to provide therapeutic benefit by enhancing the body's natural ability to heal itself. We believe that through the use of this system a patient's risk of such common disorders as heart attack and stroke will be reduced, and circulation throughout the body will be improved with numerous attendant benefits.
– United States Patent No. 5,911,698, entitled 'Treatment for Cardiovascular and Related Diseases';
– United States Patent No. 5,744,038, entitled 'Solvent Extraction Methods for Delipidating Plasma';
– United States Patent No. 4,895,558, entitled 'Autologous Plasma Delipidation Using a Continuous Flow System';
– Australian Patent Counterparts to the United States Patents Australian Patent Nos. 594964, 693458 and 695826, respectively, as well as six pending foreign patent applications related thereto;
– Pending PCT application entitled A Method of Treating Infectious Diseases;
– Pending PCT application entitled A Viral Vaccine
IPSCIO Record ID: 40994
